NASDAQ:EIDX - Eidos Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.22 +0.48 (+3.49 %)
(As of 11/15/2018 04:00 PM ET)
Previous Close$13.74
Today's Range$13.60 - $14.68
52-Week Range$8.89 - $24.75
Volume125,400 shs
Average Volume160,918 shs
Market Capitalization$536.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIDX
Previous Symbol
CUSIPN/A
Phone415-887-1471

Debt

Debt-to-Equity RatioN/A
Current Ratio28.07
Quick Ratio28.07

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.46 per share
Price / Book3.19

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-11,940,000.00
Net MarginsN/A
Return on Equity-55.61%
Return on Assets-43.13%

Miscellaneous

Employees14
Outstanding Shares36,750,000
Market Cap$536.51 million
OptionableNot Optionable

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics Inc (NASDAQ:EIDX) released its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.02. View Eidos Therapeutics' Earnings History.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Eidos Therapeutics.

What price target have analysts set for EIDX?

4 brokerages have issued 1-year price targets for Eidos Therapeutics' stock. Their predictions range from $13.00 to $36.00. On average, they expect Eidos Therapeutics' stock price to reach $27.25 in the next year. This suggests a possible upside of 91.6% from the stock's current price. View Analyst Price Targets for Eidos Therapeutics.

What is the consensus analysts' recommendation for Eidos Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.

Has Eidos Therapeutics been receiving favorable news coverage?

News headlines about EIDX stock have been trending neutral on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eidos Therapeutics earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of Eidos Therapeutics' key competitors?

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the folowing people:
  • Dr. Neil Kumar, CEO & Director (Age 39)
  • Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 61)
  • Ms. Christine E. Siu, Chief Financial Officer (Age 41)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 61)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.

When does Eidos Therapeutics' lock-up period expire?

Eidos Therapeutics' lock-up period expires on Monday, December 17th. Eidos Therapeutics had issued 6,250,000 shares in its public offering on June 20th. The total size of the offering was $106,250,000 based on an initial share price of $17.00. After the expiration of Eidos Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Eidos Therapeutics' major shareholders?

Eidos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Redmile Group LLC (2.36%), BlackRock Inc. (1.98%), Foresite Capital Management IV LLC (1.43%), Board of Trustees of The Leland Stanford Junior University (0.72%), American International Group Inc. (0.65%) and Sphera Funds Management LTD. (0.09%). Company insiders that own Eidos Therapeutics stock include Neil Kumar and Rajeev M Shah. View Institutional Ownership Trends for Eidos Therapeutics.

Which major investors are selling Eidos Therapeutics stock?

EIDX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. View Insider Buying and Selling for Eidos Therapeutics.

Which major investors are buying Eidos Therapeutics stock?

EIDX stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Foresite Capital Management IV LLC, American International Group Inc., Board of Trustees of The Leland Stanford Junior University, Tekla Capital Management LLC, Sphera Funds Management LTD. and Wexford Capital LP. Company insiders that have bought Eidos Therapeutics stock in the last two years include Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $14.22.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $536.51 million. Eidos Therapeutics employs 14 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is http://www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]


MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel